亿帆医药子公司与尚德药缘、天津尚德就ACT001达成合作

Core Viewpoint - Yifan Pharmaceutical (002019) has signed an exclusive agreement with Shangde Yaoyuan and Tianjin Shangde, granting Yifan the exclusive rights to develop, produce, and commercialize the drug ACT001 within specified regions and fields [1] Group 1: Agreement Details - Yifan Pharmaceutical's wholly-owned subsidiary, Yifan Pharmaceutical, will pay a total of 100 million yuan as an upfront payment, with options for either a cornerstone investment of 100 million yuan or a milestone payment of 50 million yuan [1] - The agreement includes a tiered revenue-sharing model based on net sales and potential revenue sharing from sublicensing outside of China [1] Group 2: Product Information - ACT001 is a first-class innovative drug with a new mechanism, developed by Shangde Yaoyuan, which has undergone multiple clinical trials in China, the United States, and Australia over the past eight years [1] - The drug targets various indications, including small cell lung cancer brain metastases and gliomas [1]